Table 1.

Clinical Trials from the database “clinicaltrials.gov” involving FMT in the treatment of melanoma, updated to 8 march 2021

Title of the study	Clinical trial number	Phase	subjects involved	ICIs	Primary outcome
Altering the Gut Microbiota of Melanoma Patients who failed immunotherapy using Fecal Microbiota Transplantation (FMT) from responding patients	NCT03353402	1	40 MM	PD-1 inhibitor	Incidence of FMT-related Adverse Events
Phase II Feasibility Study of Fecal Microbiota transplant (FMT) in Advanced transplant in melanoma Patients not responding to PD-1 Blockade	NCT03341143	2	20 MM	PD-1 inhibitor (nivolumab or pembrolizumab	Objective Response Rate
Inducing remission in Melanoma Patients with Checkpoint inhibitor therapy using Fecal Microbiota Transplantation	NCT04577729	Not Applicable	60 MM	Not specified	Progression free survival
A Phase Ib, Single Center Trial to Evaluate the Safety and Efficacy of Fecal Microbial Transplantation in Combination With Nivolumab in Subjects With Metastatic Melanoma or Non-small cell lung Cancer	NCT04521075	1b	50 MM and NSCLC	Nivolumab	Incidence of FMT-related Adverse Events
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Melanoma or Genitourinary Cancer	NCT03819296	1	800 melanoma or genitourinary cancer	Not specified	Incidence of adverse events

MM (metastatic melanoma), NSCLC (Non-Small Cell Lung Cancer).